Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Update on the CLL treatment landscape

Lydia Scarfò • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia

Lydia Scarfò, MD, Vita-Salute San Raffaele University, Milan, Italy, explains how the chronic lymphocytic leukemia (CLL) treatment landscape has evolved in recent years, including the occurrence of resistance to novel targeted therapies. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Lydia Scarfò

1:56
Defining success in CLL
Lydia Scarfò • 8 Oct 2023
2:00
Prevention of TLS with venetoclax-based regimens
Lydia Scarfò • 8 Oct 2023
1:28
Challenges with defining fitness in CLL & important comorbidities to consider when selecting therapy
Lydia Scarfò • 8 Oct 2023
2:08
Choosing between continuous versus fixed-duration therapy in CLL
Lydia Scarfò • 8 Oct 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals